Crossmark

Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab

Crossref DOI link: https://doi.org/10.1038/s41598-024-84133-5

Published Online: 2025-01-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shibutani, Masatsune

Tanda, Hideki

Kasashima, Hiroaki

Fukuoka, Tatsunari

Kashiwagi, Shinichiro

Maeda, Kiyoshi
License Information

Text and Data Mining valid from 2025-01-02

Version of Record valid from 2025-01-02
More Information

Article History

Received: 22 August 2024

Accepted: 20 December 2024

First Online: 2 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below